Suchergebnisse

Intro -- Contents -- Preface -- Chapter 1 -- Examining How Covered Entities Utilize the 340B Drug Pricing Program* -- Opening Statement of Hon. H. Morgan Griffith, a Representative in Congress from the Commonwealth of Virginia -- Prepared Statement of Hon. H. Morgan Griffith -- Opening Statement of Hon. Diana Degette, a Representative in Congress from the State of Colorado -- Opening Statement of Hon. Greg Walden, a Representative in Congress from the State of Oregon -- Prepared Statement of Hon. Greg Walden -- Opening Statement of Hon. Frank Pallone, Jr., a Representative in Congress from the State of New Jersey -- Statement of Sue Veer -- Executive Summary -- Overview of Carolina Health Centers, Inc. -- Carolina Health Centers Pharmacy Program -- Conclusion -- Statement of Michael Gifford -- The AIDS Resource Center of Wisconsin (ARCW) -- The HIV Continuum of Care -- ARCW Patient Demographic Data -- ARCW Patient Outcomes -- Financial Impact of the ARCW HIV Medical Home -- 340B Drug Pricing Program and the Fight against AIDS -- 340B at ARCW -- 340B Program Integrity at ARCW -- 340B and HRSA's Policy Clarification Notice 15-03 - Limitations on the Use of 340B Income at ARCW -- Future Changes in 340B Program Regulations -- Statement of Ronald Paulus, MD -- Executive Summary -- Statement of Record -- Mission Health Community Health Improvement Programs, Services, and Investments -- Enabling Access to Care for Everyone -- ABCCM Medical Ministry -- EMS & -- Transportation Services -- Mountain Area Medical Airlift (MAMA) -- Children's Services -- General Services -- Primary Care Medical Homes -- Region-Wide Stroke Program -- Support for Independent Physician Practice Quality -- Behavioral Health Programs -- Behavioral Health Transport -- Behavioral Health Integration -- Perinatal Substance Use Workgroup.

Introduction -- Why are prescription drugs so expensive? -- The truth behind the high costs of prescription drugs / Julie Appleby -- Higher education plays an important role in the pharma industry / Annie Waldman -- There's no immediate cure for high drug prices / Consumer Reports -- The real reason it takes so long to bring generics to market / Zachary Brennan -- There may be legitimate reasons why your drugs are so high / Michael Rosenblatt -- Why don't insurance companies cover all prescription drugs? -- Government-protected monopolies drive drug prices higher / Sydney Lupkin -- Your prescription meds may not be covered next year / Alison Kodjak -- Lowering drug prices may mean switching medications / Alison Kodjak -- Employers have the power to cut drug prices / Robert Galvin, MD, Roger Longman -- "Medically necessary" drugs are increasing prices / Marcelle Arak and Sheila Tschinkel

Testimony issued by the Government Accountability Office with an abstract that begins "Several federal programs help pay for or reduce the costs of prescription drugs for eligible individuals and entities. Three examples are the Medicaid drug rebate program, part of the joint federal-state Medicaid program that finances medical services for certain low-income people; the 340B drug pricing program, which provides discounted drug prices to certain eligible entities such as community health centers; and the Medicare Part D program, which provides a Medicare drug benefit for the elderly and certain disabled people. The price information drug manufacturers report under these federal programs affects related federal spending. Spending is also affected by the extent to which federal oversight ensures the accuracy of this information. GAO was asked to provide information related to the oversight of prescription drug pricing practices that affect these federal programs. This testimony focuses on the oversight of drug pricing related to the three programs and the implications for future congressional oversight. This testimony is based on recent GAO reports examining these programs and related work by the Department of Health and Human Services Office of Inspector General and others."

More than a dozen speakers held forth on May 5 at the Leonard Davis Institute of Health Economics (LDI) conference, "A Prescription for the Future of Drug Pricing." And while there was a spirited debate over the role of Pharmacy Benefit Managers and other issues, there was wide agreement that drug pricing is poised to […]

PURPOSE: To compare US and international drug pricing for commonly prescribed intravitreal and topical ophthalmic medications. DESIGN: Cross-sectional observational study. METHODS: For twenty-five commonly used ophthalmic medications (three intravitreal, twenty-two topical), we obtained 2017 Q3 US average wholesale price (AWP), drug acquisition cost or consumer pricing through US government health insurance plans (Veterans Affairs (VA), Medicaid, Medicare Part B, Medicare Part D) and commercial drug plans (CVS Caremark and Navitus Health Solutions), online pricing without insurance through a large US warehouse retailer (Costco), and international drug pricing through government-sponsored health plans in Italy, Spain, Turkey, Canada, and Japan. MAIN OUTCOME MEASURES: Drug acquisition costs and consumer pricing of ophthalmic drugs through various payment systems. All prices were converted to US dollars. RESULTS: For intravitreal medications in the United States, aflibercept and ranibizumab were priced similarly to each other and more expensive than dexamethasone implants. Pricing of aflibercept and ranibizumab through government health insurance plans in Italy, Spain, Turkey, Canada, and Japan were less expensive by as much as 84.3% compared to the United States. For topical medications in the United States, pricing varied significantly both across different classes of medications but also between non-branded and branded medications. Drug acquisition costs through the VA and Medicaid were inexpensive on average, but pricing through a hospital-employee drug insurance plan offered the smallest range (between $2.35 and $60.00). In all five non-US countries studied, each topical medication with the exception of cyclosporine emulsion and difluprednate was less expensive than $100, and 94.4% of topical medications in these countries had a non-branded or branded option less expensive than $50. CONCLUSIONS: In the United States, for topical more than intravitreal medications, significant price variation exists across both ...